secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOTRICITY INC. (BTCY)
CIK:        0001630113
Form:       8-K
Filed at:   2021-11-05T23:59:59+00:00
Accession:  0001493152-21-027370
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biotricity Q2 FY2022 revenue $1.81M (+143% YoY); net loss $11M includes $5.46M one-time costs
--------------------------------------------------------------------------------

- Revenue of $1.81 million, up 143% year-over-year; gross margin 62%.
- Net loss $11.0M ($0.256/sh); adjusted net loss $5.2M ($0.128/sh) excluding $5.46M Nasdaq up-listing costs.
- Ended quarter with $11.7 million cash, strongest balance sheet ever.
- Announced Biokit personal medical device kit for home-use cardiac monitoring; commercial launch planned Q1 2022.
- Revenue impacted by hurricanes and COVID clinic closures in southern US; expects recapture in subsequent months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630113/000149315221027370/0001493152-21-027370-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630113/000149315221027370/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-027370

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer